NervGen to Detail Function Improvement Data at Spinal Cord Injury Symposium
Event summary
- NervGen Pharma will present clinical data from the Phase 1b/2a CONNECT SCI Study at Unite2Fight Paralysis’ symposium on February 15, 2026.
- The presentation, featuring CEO Adam Rogers, will focus on durable improvements in function, independence, and quality of life observed in chronic spinal cord injury patients.
- The symposium, held in Washington, DC, brings together scientists, clinicians, policymakers, and patient advocates.
- NervGen’s lead candidate, NVG-291, is a subcutaneously administered peptide and has received Fast Track and Orphan Drug designations.
The big picture
NervGen's progress represents a significant, albeit early, step toward a pharmacologic treatment for spinal cord injury, a market with substantial unmet need and limited therapeutic options. The company’s focus on durable improvements in quality of life, rather than just motor function, aligns with a growing patient-centric approach in drug development. The symposium provides a crucial platform for NervGen to engage with key stakeholders and influence the evolving treatment landscape.
What we're watching
- Clinical Validation
- The specifics of the data presented at the symposium will be critical in assessing the clinical significance of NVG-291’s observed improvements, particularly given the chronic nature of the patient population.
- Regulatory Pathway
- How the FDA and EMA interpret the CONNECT SCI data will heavily influence the design and potential success of future Phase 3 trials and the overall commercial viability of NVG-291.
- Competitive Landscape
- The presentation’s reception within the spinal cord injury research community will reveal how NervGen’s approach stacks up against emerging therapies and alternative treatment paradigms.
